Novel N-(3-ethynyl Phenyl)-6,7-bis(2-methoxyethoxy)Quinazoline-4-amine Derivatives: Synthesis, Characterization, Anti-cancer Activity, In-silico and DFT Studies

被引:2
作者
Dash, Amitananda [1 ]
Vaddamanu, Guruswamy [2 ]
Karreddula, Raja [3 ]
Manubolu, Surya Surendra Babu [4 ]
Kumari, G. Pavana [1 ]
Mulakayala, Naveen [2 ]
机构
[1] Sri Sathya Sai Inst Higher Learning, Anantapur 515001, Andhra Prades, India
[2] SVAK Life Sci, ALEAP Ind Area, Hyderabad 500090, India
[3] Rajeev Gandhi Mem Coll Engn & Technol Autonomous, Dept Chem, Nandyal 518501, Andhra Prades, India
[4] GITAM Univ, Dept Chem, Hyderabad Campus, Hyderabad 502329, Telangana, India
关键词
Erlotinib; synthesis; anti-cancer activity; NCI-60; docking studies; protein-ligand interaction; DFT studies; CELL LUNG-CANCER; DRUG DISCOVERY; MOLECULAR DOCKING; STATISTICS; ULTRASOUND; INHIBITORS; ERLOTINIB;
D O I
10.2174/0118715206276286231220055233
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer is one of the most common reasons for mortality in the world. A continuous effort to develop effective anti-cancer drugs with minimum side effects has become necessary. The use of small-molecule drugs has revolutionized cancer research by inhibiting cancer cell survival and proliferation. Quinazolines are a class of bioactive heterocyclic compounds with active pharmacophores in several anti-cancer drugs. Such small molecule inhibitors obstruct the significant signals responsible for cancer cell development, thus blocking these cell signals to prevent cancer development and spread. Objective: In the current study, novel quinazoline derivatives structurally similar to erlotinib were synthesized and explored as novel anti-cancer agents. Methods: All the synthesized molecules were confirmed by spectroscopic techniques like H-1 NMR, C-13 NMR, and ESI-MS. Various techniques were applied to study the protein-drug interaction, DFT analysis, Hirshfeld surface, and target prediction. The molecules were screened in vitro for their anti-cancer properties against 60 human tumor cell lines. The growth inhibitory properties of a few compounds were studied against the MCF7 breast cancer cell line. Results: The activity of compounds 9f, 9o, and 9s were found to be active. However, compound 9f is more active when compared with other compounds. Conclusion: Some synthesized compounds were active against different cancer cell lines. The in-vitro study results were found to be in agreement with the predictions from in-silico data. The selected molecules were further subjected to get the possible mechanism of action against different cancer cells.
引用
收藏
页码:514 / 532
页数:19
相关论文
共 62 条
[11]  
Dennington R., 2016, GaussView
[12]   Prediction of drug absorption using multivariate statistics [J].
Egan, WJ ;
Merz, KM ;
Baldwin, JJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) :3867-3877
[13]  
Faraj Fadhil Lafta, 2014, ScientificWorldJournal, V2014, P212096, DOI 10.1155/2014/212096
[14]   A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases [J].
Ghose, AK ;
Viswanadhan, VN ;
Wendoloski, JJ .
JOURNAL OF COMBINATORIAL CHEMISTRY, 1999, 1 (01) :55-68
[15]   Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[bf][1,4] thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives [J].
Gudisela, Mura Reddy ;
Srinivasu, N. ;
Mulakayala, Chaitanya ;
Bommu, Praveen ;
Rao, M. V. Basaveswara ;
Mulakayala, Naveen .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (17) :4140-4145
[16]   Recent development of peptide coupling reagents in organic synthesis [J].
Han, SY ;
Kim, YA .
TETRAHEDRON, 2004, 60 (11) :2447-2467
[17]   Recent developments in topoisomerase-targeted cancer chemotherapy [J].
Hevener, Kirk E. ;
Verstak, Tatsiana A. ;
Lutat, Katie E. ;
Riggsbee, Daniel L. ;
Mooney, Jeremiah W. .
ACTA PHARMACEUTICA SINICA B, 2018, 8 (06) :844-861
[18]   Discovery of small molecule cancer drugs: Successes, challenges and opportunities [J].
Hoelder, Swen ;
Clarke, Paul A. ;
Workman, Paul .
MOLECULAR ONCOLOGY, 2012, 6 (02) :155-176
[19]   Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp) [J].
Javle, M. M. ;
Oh, D-Y ;
Ikeda, M. ;
Yong, W-P ;
Hsu, K. ;
Lindmark, B. ;
McIntyre, N. ;
Firth, C. .
ESMO OPEN, 2022, 7 (01)
[20]   Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66